Mesenchymal stem/stromal cells: Developmental origin, tumorigenesis and translational cancer therapeutics

Li, Chenghai; Zhao, Hua; Wang, Bin

doi:10.1016/j.tranon.2020.100948

Cited by 42 publications

(52 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main risks of MSCs are proinflammatory properties, tumorigenicity, and fibrosis [ 58 ]. Among them, tumorigenicity is the most serious and many studies have shown that MSCs have the ability to converse into tumors as well as the ability to trigger tumor development [ 59 ]. The excessive productions of cytokines by MSC, such as growth factors and chemokines, directly act on surface receptors of cancer cells, thereby regulating tumor enhancement [ 60 ].…”

Section: At-msc Collection Approaches For Treatment Of Noamentioning

confidence: 99%

Mesenchymal stromal/stem cells and their exosomes for restoration of spermatogenesis in non-obstructive azoospermia: a systemic review

et al. 2021

View full text Add to dashboard Cite

Stem cells have been introduced as new promising therapeutic agents in treatment of degenerative diseases because of having high differentiation potential while maintaining the ability to self-replicate and retaining features of their source cells. Among different type of cell therapies, mesenchymal stromal/stem cell (MSC) therapy is being increasingly developed as a new way to treat structural defects that need to be repaired and regenerated. Non-obstructive azoospermia (NOA) is a reproductive disease in men that causes infertility in 10% of infertile men. Based on in vitro studies, MSCs from different tissue sources have been differentiated into germ cells or gamete progenitor cells by simple methods in both male and female. On the other hand, the therapeutic effects of MSCs have been evaluated for the treatment of NOA animal models created by chemical or surgical compounds. The results of these studies confirmed successful allotransplantation or xenotransplantation of MSCs in the seminiferous tubules. As well, it has been reported that exosomes secreted by MSCs are able to induce the process of spermatogenesis in the testes of infertile animal models. Despite numerous advances in the treatment of reproductive diseases in men and women with the help of MSCs or their exosomes, no clinical trial has been terminated on the treatment of NOA. This systematic review attempts to investigate the possibility of MSC therapy for NOA in men.

show abstract

Section: At-msc Collection Approaches For Treatment Of Noamentioning

confidence: 99%

Mesenchymal stromal/stem cells and their exosomes for restoration of spermatogenesis in non-obstructive azoospermia: a systemic review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Moreover, due to the multifaceted role of MSCs in tumor progression, MSC-based anti-cancer therapies guide new strategies to overcome therapy resistance. For example, MSCs are being exploited as selective carriers for drug delivery in cancers because of their strong tropism and recruitment to tumors (Li et al, 2021). Several preclinical studies have been conducted to exploit the tumor-targeting ability of MSCs, using MSCs as an excellent in vivo vehicle to deliver tumor-killing drugs (Kim et al, 2015;Yin et al, 2018).…”

Section: Differentiating Into Caf or Cscmentioning

confidence: 99%

The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment

Zhou

Yang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Cancer cells resistance to various therapies remains to be a key challenge nowadays. For a long time, scientists focused on tumor cells themselves for the mechanisms of acquired drug resistance. However, recent evidence showed that tumor microenvironment (TME) is essential for regulating immune escape, drug resistance, progression and metastasis of malignant cells. Reciprocal interactions between cancer cells and non-malignant cells within this milieu often reshape the TME and promote drug resistance. Therefore, advanced knowledge about these sophisticated interactions is significant for the design of effective therapeutic approaches. In this review, we highlight cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), myeloid-derived suppressor cells (MDSCs), T-regulatory lymphocytes (Tregs), mesenchymal stem cells (MSCs), cancer-associated adipocytes (CAAs), and tumor endothelial cells (TECs) existing in TME, as well as their multiple cross-talk with tumor cells, which eventually endows tumor cells with therapeutic resistance.

show abstract

“…The unique properties of mesenchymal stromal/stem cells (MSCs) to self‐renew together with their and immunomodulatory characteristics have rendered MSCs attractive to researchers and clinicians as a means of cellular therapy [32–34]. The broad repertoire of secreted trophic factors (cytokines), commonly referred to as the MSC secretome, exhibiting diverse functions such as immunomodulation, anti‐inflammatory activity, angiogenesis and anti‐ apoptotic, has gained immense attention in the past few years [35].…”

Section: Mesenchymal Stromal Cellsmentioning

confidence: 99%

“…The source of MSC and donor characteristics and its significance to the disease being treated, the route of administration and the dose and frequency of MSC to be administered is not known and the parameters to be monitored for clinical effectiveness are not established and often vary for different diseases. Furthermore, the long‐term safety of MSC‐based therapies remains poorly established and continues to pose a major limitation to translating MSCs into clinical practice [32,33]. In view of the above challenges, many MSC therapies have not been able to meet primary efficacy end points.…”

Section: Mesenchymal Stromal Cellsmentioning

confidence: 99%

Proven and unproven cell therapies – what we have learned so far?

Lim

2021

ISBT Science Series

View full text Add to dashboard Cite

The exciting advancement in cell therapies in both cancer and regenerative medicine provides alternative therapeutic opportunities for patients with advanced diseases who have exhausted all treatment options. However, with the emergence of new technologies and innovations this also brings about “unproven” cell‐ and tissue‐based interventions that have not been fully evaluated in clinical trials. Such interventions have resulted in injuries and deaths in patients. Collectively, these practices increase the potential for patient exploitation and harm through the imposition of medical and financial risks. Recognizing this worrying situation, in April 2020, European Medicine Agency (EMA), committee for Advances Therapies advised patients and the general public to be cautious unproven cell‐based therapies. Likewise, the Food and Drug Administration (FDA) has posted information about products marketed as stem cells, mesenchymal stromal cells (MSCs) or other regenerative medicine products, including the conditions for which they are approved, and which products are not approved. Though both EMA and FDA recognize the promise of cell‐based therapies for treating patients with serious diseases, both concur that well‐designed clinical trials and regulatory oversight are necessary to ensure safety, efficacy and quality of the therapies. In this review, I will mention proven cell therapies in the haematopoietic stem cell transplant setting and in the form of chimeric antigen receptor (CAR) T‐cell therapies and briefly mention how these therapies have evolved over time, the learning curve and scientific progress in these therapies. I will then mention briefly about MSCs and focus on both the proven and unproven aspects of MSC.

show abstract

Mesenchymal stem/stromal cells: Developmental origin, tumorigenesis and translational cancer therapeutics

Cited by 42 publications

References 106 publications

Mesenchymal stromal/stem cells and their exosomes for restoration of spermatogenesis in non-obstructive azoospermia: a systemic review

Mesenchymal stromal/stem cells and their exosomes for restoration of spermatogenesis in non-obstructive azoospermia: a systemic review

The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment

Proven and unproven cell therapies – what we have learned so far?

Contact Info

Product

Resources

About